AI-assisted, human-published
12/19/2025 /Funding Events
Sanegene Bio Secures Over $110 Million in Series B Financing for RNAi Programs and Disease Development
Sanegene Bio raises more than $110 million to advance RNAi programs and broaden development in metabolic, cardiovascular, and autoimmune diseases, reflecting growing interest in RNA-based medicines and investor confidence in advanced delivery platforms.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com